Emany Sravan Kumar 4
4 · Beam Therapeutics Inc. · Filed Jan 5, 2026
Insider Transaction Report
Form 4
Emany Sravan Kumar
Chief Financial Officer
Transactions
- Sale
Common Stock
2025-12-31$27.10/sh−6,294$170,567→ 73,706 total
Footnotes (1)
- [F1]These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on December 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 11, 2025.